Biodel Inc. to Report Fourth Quarter Fiscal Year 2010 Financial Results on December 9, 2010

DANBURY, Conn., Dec. 6, 2010 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) will issue its fourth quarter fiscal year 2010 financial results on December 9, 2010. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.

Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at http://www.biodel.com. The audio webcast will be archived and available for replay through the website.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel's product candidates are developed using VIAdel technology, which reformulates existing FDA-approved peptide drugs. Linjeta is Biodel's most advanced product candidate and has been reviewed by the FDA which issued a complete response letter. Earlier-stage product candidates include VIAtab, a sublingual tablet formulation of insulin, a line of basal insulins, and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company's website at www.biodel.com.

BIOD-G

SOURCE Biodel Inc.